CANNABINOIDERGIC REGULATION OF FUNCTIONAL STATE OF HEART (PART I)
https://doi.org/10.29001/2073-8552-2017-32-3-7-13
Abstract
It was found that cannabinoids in anesthetized animals cause prolonged hypotension and bradycardia, which are the result of the stimulation of the CB1 receptor. The endogenous cannabinoids are not involved in the regulation of heart rate and blood pressure in intact animals. Studies carried out in patients with coronary heart disease have shown that marijuana can cause angina. It is established that cannabinoids induce prolonged hypotension and bradycardia, which may be preceded by transient tachycardia and hypertension associated with activation of the vanilloid TRPV1 receptor. Prolonged hypotension is a result of direct action of cannabinoids on the arteries.
About the Authors
A. V. Krylatov
Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk
Russian Federation
Russian Federation
V. Yu. Serebrov
National Research Tomsk Polytechnic University, Tomsk;
Siberian State Medical University, Tomsk
Russian Federation
Russian Federation
O. E. Vaizova
Siberian State Medical University, Tomsk
Russian Federation
Russian Federation
E. Yu. Dyakova
National Research Tomsk State University, Tomsk
Russian Federation
Russian Federation
References
1. Mechoulam R., Gaoni Y. Hashish — IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids // Tetrahedron. — 1965. — Vol. 21, No. 5. — P. 1223–1229.
2. Matsuda L.A., Lolait S.J., Brownstein M.J. et al. Structure of a can- nabinoid receptor and functional expression of the cloned cDNA // Nature. — 1990. — Vol. 346, No. 6284. — P. 561–564.
3. Howlett A.C., Blume L.C., Dalton G.D. CB1 cannabinoid receptors and their associated proteins // Curr. Med. Chem. — 2010. — Vol. 17, No. 14. — P. 1382–1393.
4. Bonz A., Laser M., Küllmer S. et al. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle // J. Cardiovasc. Pharmacol. — 2003. — Vol. 41, No. 4. — P. 657–664.
5. Wagner J.A., Hu K., Karcher J. et al. CB1 cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction // Br. J. Pharmacol. — 2003. — Vol. 138, No. 7. — P. 1251–1258.
6. Wang P.F., Jiang L.S., Bu J. et al. Cannabinoid-2 receptor activation protects against infarct and ischemia/reperfusion heart injury // J. Cardiovasc. Pharmacol. 2012. — Vol. 59, No. 4. — P. 301–307.
7. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids // Nature. — 1993. — Vol. 365, No. 6441. — P. 61–65.
8. Dalton G.D., Bass C.E., Van Horn C.G., Howlett A.C. Signal transduction via cannabinoid receptors // CNS Neurol. Disord. Drug Targets. — 2009. — Vol. 8, No. 6. — P. 422–431.
9. Galiegue S., Mary S., Marchand J. et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations // Eur. J. Biochem. — 1995. — Vol. 232, No. 1. — P. 54–61.
10. Onaivi E.S., Ishiguro H., Gong J.P. et al. Endocannabinoids and the cardiovascular system in health and disease. In: Endocannabinoids // Pertwee, Roger G. (Ed.), Handb. Exp. Pharmacol. — 2015. — No. 231. — P. 393–422.
11. Shmist Y.A., Goncharov I., Eichler M. et al. Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production // Mol. Cell. Biochem. — 2006. — Vol. 283, No. 1–2. — P. 75–83.
12. Weis F., Beiras-Fernandez A., Sodian R. et al. Substantially altered expression pattern of cannabinoid receptor 2 and activated en-docannabinoid system in patients with severe heart failure // J. Mol. Cell. Cardiol. — 2010. — Vol. 48, No. 6. — P. 1187–1193.
13. Sawzdargo M., Nguyen T., Lee D.K. et al. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, ψGPR53 and GPR55: GPR55 is extensively expressed in human brain // Brain Res. Mol. Brain Res. — 1999. — Vol. 64, No. 2. — P. 193–198.
14. Ryberg E., Larsson N., Sjögren S. et al. The orphan receptor GPR55 is a novel cannabinoid receptor // Br. J. Pharmacol. — 2007. — Vol. 152, No. 7. — P. 1092–1101.
15. Devane W.A., Hanus L., Breuer A. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor // Science. — 1992. — Vol. 258, No. 5090. — P. 1946–1949.
16. Mechoulam R., Ben-Shabat S., Hanuš L. et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors // Biochem. Pharmacol. — 1995. — Vol. 50, No. 1. — P. 83–90.
17. Hanus L., Abu-Lafi S., Fride E. et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor // Proc. Natl. Acad. Sci. USA. — 2001. — Vol. 98, No. 7. — P. 3662–3665.
18. Leggett J.D., Aspley S., Beckett S.R. et al. Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors // Br. J. Pharmacol. — 2004. — Vol. 141, No. 2. — P. 253–262.
19. Milman G., Maor Y., Abu-Lafi S. et al. N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties // Proc. Natl. Acad. Sci. USA. — 2006. — Vol. 103, No. 7. — P. 2428–2433.
20. Gomes I., Grushko J.S., Golebiewska U. et al. Novel endogenous peptide agonists of cannabinoid receptors // FASEB J. — 2009. — Vol. 23, No. 9. — P. 3020–3029.
21. Pertwee R.G. Endocannabinoids and their pharmacological actions. In: Endocannabinoids // Pertwee Roger G. (Ed.), Handb. Exp. Pharmacol. — 2015. — No. 231. — P. 1–37.
22. Holman E.A., Guijarro A., Lim J., Piomelli D. Effects of acute stress on cardiac endocannabinoids, lipogenesis, and inflammation in rats // Psychosom. Med. — 2014. — Vol. 76, No. 1. — P. 20–28.
23. Tuma R.F., Steffens S. Targeting the endocannabinod system to limit myocardial and cerebral ischemic and reperfusion injury // Curr. Pharm. Biotechnol. — 2012. — Vol. 13, No. 1. — P. 46–58.
24. Wagner J.A., Abesser M., Harvey-White J., Ertl G. 2-Arachidonyl-glycerol acting on CB1 cannabinoid receptors mediates delayed cardioprotection induced by nitric oxide in rat isolated hearts // J. Cardiovasc. Pharmacol. — 2006. — Vol. 47, No. 5. — P. 650–655.
25. Varga K., Wagner J.A., Bridgen D.T., Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension // FASEB J. — 1998. Vol. 12, No. 11. P. 1035–1044.
26. Cabral G.A., Ferreira G.A., Jamerson M.J. Endocannabinoids and the immune system in health and disease. In: Endocannabinoids // Pertwee Roger G. (Ed.) Handb. Exp. Pharmacol. — 2015. — No. 231. — P. 185–211.
27. Cascio M.G., Marini P. Biosynthesis and fate of endocannabinoids. In: Endocannabinoids // Pertwee Roger G. (Ed.), Handb. Exp. Pharmacol. — 2015. — No. 231. — P. 39–58.
28. Hollister L.E., Richards R.K., Gillespie H.K. Comparison of tetrahydrocannabinol and synhexl in man // Clin. Pharmacol. Ther. — 1968. — Vol. 9, No. 6. — P. 783–791.
29. Domino E.F. Neropsychologic studies of marihuana. Some synthetic and natural THC derivates in animals and man // Ann. N.Y. Acad. Sci. — 1971. — No. 191. — P. 166–191.
30. Malit L.A., Johnstone R.E., Bourke D.I. et al. Intravenous Δ9-tetrahydrocannabinol: Effects on ventilatory control and cardiovascular dynamics // Anesthesiology. — 1975. — Vol. 42, No. 6. — P. 666–673.
31. Dewey W.L., Jenkins J., O’Rourke T., Harris L.S. The effect of chronic administration of trans-Δ9-tetrahydrocannabinol on behavior and the cardiovascular system of dogs // Arch. Int. Pharmacodyn. Ther. — 1972. — Vol. 198, No. 1. — P. 118–131.
32. Cavero I., Ertel R., Buckley J.P., Jandhyala B.S. Effects of (-)-Δ9-trans-tetrahydrocannabinol on regional blood flow in anesthetized dogs // Eur. J. Pharmacol. — 1972. — Vol. 20, No. 3. — P. 373–376.
33. Perez-Reyes M., Timmons M.C., Lipton M.A. et al. Intravenous injection in man of Δ9-tetrahydrocannabinol and 11-OH-Δ9-tetrahydrocannabinol // Science — 1972. — Vol. 177, No. 49. — P. 633–635.
34. Perez-Riyes M., Timmons M.C., Davis K.H., Wall E.M. A comparison of the pharmacological activity in man of intravenously administered Δ9-tetrahydrocannabinol, cannabinol, and cannabidiol // Experientia. — 1973. — Vol. 29, No. 11. — P. 1368–1369.
35. Cavero I., Buckley J.P., Jandhyala B.S. Hemodynamic and myocardial effects of (-)-Δ9-trans-tetrahydrocannabinol in anesthetized dogs // Eur. J. Pharmacol. — 1973. — Vol. 24, No. 2. — P. 243–251.
36. Gorelick D.A., Goodwin R.S., Schwilke E. et al. Tolerance to effects of high-dose oral Δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers // J. Anal. Toxicol. — 2013. — Vol. 37, No. 1. — P. 11–16.
37. Kaymakcalan S., Sivil S. Lack of tolerance to the bradycardic effect of D9-trans-tetrahydrocannabinol in rats // Pharmaco- logy. — 1974. — Vol. 12, No. 4–5. — P. 290–295.
38. Adams M.D., Chait L.D., Earnhardt J.T. Tolerance to the cardiovascular effects of Δ9-tetrahydrocannabinol in the rat // Br. J. Pharmacol. — 1976. — Vol. 56, No. 1. — Р. 43–48.
39. Hine B., Torrelio M., Gershon S. Analgesic, heart rate, and temperature effects of D8-THC during acute and chronic administration to conscious rats // Pharmacology — 1977. — Vol. 15, No. 1. — P. 65–72.
40. Hine B. Morphine and D9-tetrahydrocannabinol: two-way cross tolerance for antinociceptive and heart-rate responses in the rat // Psychopharmacology. — 1985. — Vol. 87, No. 1. — P. 34–38.
41. Jandhyala B.S., Hamed A.T. Pulmonary and systemic hemodynamic effects of delta9-tetrahydrocannabinol in conscious and morphine-chloralose-anesthetized dogs: anesthetic influence on drug action // Eur. J. Pharmacol. — 1978. — Vol. 53, No. 1. — P. 63–68.
42. Stark P., Dews P.B. Cannabinoids. II. Cardiovascular effects // J. Pharmacol. Exp. Ther. — 1980. — Vol. 214, No. 1. — P. 131–138.
43. Kawasaki H., Watanabe S., Ueki S. Effects of chronic administration of delta 9-tetrahydrocannabinol on the cardiovascular system, and pressor and behavioral responses to brain stimulation in freely moving rats // Eur. J. Pharmacol. — 1980. — Vol. 65, No. 1. — P. 63–69.
44. Friedman E., Gershon S., Hine B., Torrelio M. Cardiovascular effects of D9-tetrahydrocannabinol in conscious and anesthetized dogs // Br. J. Pharmacol. — 1977. — Vol. 59, No. 4. — P. 561–563.
45. Маслов Л.Н., Хедрик Дж.П., Мешоулам Р. и др. Роль транс-активации рецепторов в кардиопротекторных эффектах прекондиционирования и посткондиционирования // Рос. физиол. журн. — 2012. — Т. 98, № 3. — С. 305–317.
46. Cavero I., Lokhandwala M.F., Buckley J.P., Jandhyala B.S. The effect of (-)-Δ9-trans-tetrahydrocannibinol on myocardial con-tractility and venous return in anesthetized dogs // Eur. J. Pharmacol. — 1974. — Vol. 29, No. 1. — P. 74–82.
47. Aronow W.S., Cassidy J. Effect of marihuana and placebo-marihuana smoking on angina pectoris // N. Engl. J. Med. — 1974. — Vol. 291, No. 2. — P. 65–67.
48. Vivan J.A., Kishioka S., Butelman E.R. et al. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A // J. Pharmacol. Exp. Ther. — 1998. — Vol. 286, No. 2. — P. 697–703.
49. Vidrio H., Sanchez-Salvatori M.A., Medina M. Cardiovascular effects of (-)-11-OH-D8-tetrahydrocannabinol-dimethylheptyl in rats. // J. Cardiovasc. Pharmacol. — 1996. — Vol. 28, No. 2. P. 332–336.
50. Pertwee R.G. Pharmacology of cannabinoid receptor ligands // Curr. Med. Chem. — 1999. — Vol. 6, No. 8. — P. 635–664.
51. Lake K.D., Compton D.R., Varga K., Martin B.R., Kunos G. Can-nabinoid-induced hypotension and bradycardia in rats is mediated by CB1-like cannabinoid receptors // J. Pharmacol. Exp. Ther. — 1997. — Vol. 81, No. 3. — P. 1030–1037.
52. Krylatov A.V., Maslov L.N., Ermakov S.Yu. et al. Significance of car- diac cannabinoid receptors in regulation of cardiac rhythm, myo- cardial contractility, and electrophysiologic process in heart // Biol. Bull. — 2007. — Vol. 34, No. 1. — P. 28–35.
53. Malinowska B., Kwolek G., Gothert M. Anandamide and methanandamide induce both vanilloid VR1- and cannabinoid CB1 receptor-mediated changes in heart rate and blood pressure in anaesthetized rats // Naunyn-Schmiedeberg’s Arch. Pharma-col. 2001. — Vol. 364, No. 6. — P. 562–569.
54. Gardiner S.M., March J.E., Kemp P.A., Bennett T. Complex regional haemodynamic effects of anandamide in conscious rats // Br. J. Pharmacol. — 2002. — Vol. 135, No. 8. — P. 1889–1896.
55. Pacher P., Batkai S., Kunos G. Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice // J. Physiol. — 2004. — Vol. 558, Pt. 2. — P. 647–657.
56. Zuurman L., Passier P.C., de Kam M. et al. Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers // J. Psychopharmacol. — 2009. — Vol. 23, No. 6. — P. 633–644.
57. Stanley C.P., Hind W.H., Tufarelli C., O’Sullivan S.E. Cannabidiol causes endothelium-dependent vasorelaxation of human mes-enteric arteries via CB1 activation // Cardiovasc. Res. — 2015. — Vol. 107, No. 4. — P. 568–578.
58. AlSuleimani Y.M., Hiley C.R. The GPR55 agonist lysophosphatidylinositol relaxes rat mesenteric resistance artery and induces Ca2+ release in rat mesenteric artery endothelial cells // Br. J. Pharmacol. — 2015. — Vol. 172, No. 12. — P. 3043–3057.
59. O’Sullivan S.E. Endocannabinoids and the cardiovascular system in health and disease. In: Endocannabinoids // Pertwee, Roger G. (Ed.), Handb. Exp. Pharmacol. — 2015. — Vol. 231. — P. 393–422.
Review
For citations:
Krylatov A.V., Serebrov V.Yu., Vaizova O.E., Dyakova E.Yu. CANNABINOIDERGIC REGULATION OF FUNCTIONAL STATE OF HEART (PART I). Siberian Journal of Clinical and Experimental Medicine. 2017;32(3):7-13. (In Russ.) https://doi.org/10.29001/2073-8552-2017-32-3-7-13
Views:
1119
.png)
Email this article 